Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$204.76 USD

204.76
878,984

-0.06 (-0.03%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More

Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.

The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals

The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals

Alkermes' (ALKS) Earnings and Sales Beat Estimates in Q3

Alkermes (ALKS) beats estimates in the third quarter of 2019. Its proprietary products, especially Aristada, drive revenues.

Sweta Killa headshot

Biotech ETFs Surge on a Flurry of Positive News

The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.

Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates

Key highlights of the past week include acquisition news, and regulatory and pipeline updates.

Earnings Data Deluge

Earnings Data Deluge

Mark Vickery headshot

Biogen (BIIB) Up 40% on Alzheimer's Drug & More

This is about as "game changer" as a drug can get, at least in the early stages.

Biogen (BIIB) Beats on Q3 Earnings, Eyes FDA Nod for Aducanumab

Biogen (BIIB) beats estimates for both earnings and sales in the third quarter. It is set to pursue FDA approval of aducanumab. Shares skyrocket in pre-market trading.

Biogen (BIIB) Q3 Earnings & Sales Beat Estimates

Biogen (BIIB) beats estimates for both earnings and sales in the third quarter. It is set to pursue FDA approval of aducanumab. Shares skyrocket in pre-market trading.

Sweta Killa headshot

Earnings Surprise May Lift Stocks: Buy These Growth ETFs

Market participants are betting on the record-high U.S. indices as about 120 S&P 500 companies are scheduled to release their results this week.

Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?

Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth

Biogen Strengthens MS & SMA Portfolio as Competition Lurks

Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon face competition.

The Zacks Analyst Blog Highlights: Verizon Communications, PepsiCo, Biogen, Bank of New York ??? Mellon and Cerner

The Zacks Analyst Blog Highlights: Verizon Communications, PepsiCo, Biogen, Bank of New York ??? Mellon and Cerner

Mark Vickery headshot

Top Stock Reports for Verizon, PepsiCo & Biogen

Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications (VZ), PepsiCo (PEP) and Biogen (BIIB).

Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More

Key highlights of the past week include regulatory and pipeline updates, licensing deals, and more.

Biogen's Two MS Drugs Get CHMP Nod for Use in Pregnancy

Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex

Biogen's New Study to Test Higher Dose of SMA Drug Spinraza

Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.

Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019

Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.

Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More

Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.

Roche's Gazyva Now a Breakthrough Therapy for Lupus Nephritis

Roche's (RHHBY) lymphoma drug, Gazyva, obtains Breakthrough Therapy designation in the United States for lupus nephritis.

The Zacks Analyst Blog Highlights: Biogen, Crocs, Casey's General Stores and Clean Harbors

The Zacks Analyst Blog Highlights: Biogen, Crocs, Casey's General Stores and Clean Harbors

Biogen Stops Late-Stage Studies on Alzheimer's Candidate

Biogen (BIIB) and its Japanese partner, Eisai receive another setback as they discontinue two late-stage studies evaluating elenbecestat in patients with Alzheimer's disease.

Tirthankar Chakraborty headshot

What September Doldrums? Here's Why Stocks Are Moving Higher

From ECB stimulus to trade optimism, all are helping stocks eke out gains. And let's admit that recession may be coming, but it isn't around the corner.

Supriyo Bose headshot

Top 5 ROE Stocks to Profit as Sino-US Trade Tensions Abate

ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.